+39 02 610346.1 - info@newron.com

Latest press releases

  • 12Jan
    Zambon Launches Xadago® (Safinamide) In Switzerland For Patients With Parkinson’s Disease


  • 2Dec
    Newron initiates U.S. Phase II trial in patients with schizophrenia


  • 20Nov
    Newron Completes 5.4 Million USD/CHF Private Placement with U.S. Biotechnology/Healthcare Specialist Fund


  • 13Nov
    Swissmedic approves Xadago® for use in Parkinson’s disease


  • 28Oct
    Newron Pharmaceuticals Announces Planned Pivotal Trial Design for Sarizotan for Patients with Rett Syndrome, a Rare Neurodevelopmental Disease


  • 7Oct
    Meiji announces Initiation of Phase II/III and Long-term Clinical Trials of ME2125 (safinamide) for the Treatment of PD

View All

Newron share price


View Event Calendar